Neĭmark A I, Iakovets Ia V
Ter Arkh. 1994;66(8):57-60.
A total of 83 patients with chronic renal failure (CRF) at azotemia stage (S. I. Riabov's classification) complicating pyelonephritis were treated: 19 patients received symptomatic standard therapy (group 1), 29 patients received combined therapy with enterosorption (group 2), 35 patients received combined treatment with plasmapheresis (group 3). The efficacy of the treatments was controlled by platelet tests (platelet, coagulative hemostasis, fibrinolytic plasma activity) and parameters of kallikrein-kinin system. Treatment results in group 1 are characterized as poor: insignificant improvement of uremia, DIC syndrome against unchanged inhibition of kallikrein-kinin system. Group 2 patients achieved moderate response: uremia reduced to normal azotemia values, DIC syndrome and inhibition of kallikrein-kinin system reduced. Patients of group 3 got disappeared DIC syndrome and normal kallikrein-kinin system against high azotemia.
共治疗了83例处于氮质血症期（S.I.里亚博夫分类法）并合并肾盂肾炎的慢性肾衰竭（CRF）患者：19例患者接受了对症标准治疗（第1组），29例患者接受了联合肠吸附治疗（第2组），35例患者接受了联合血浆置换治疗（第3组）。通过血小板检测（血小板、凝血止血、纤维蛋白溶解血浆活性）和激肽释放酶-激肽系统参数来控制治疗效果。第1组的治疗结果较差：尿毒症改善不明显，弥漫性血管内凝血（DIC）综合征存在，而激肽释放酶-激肽系统的抑制作用未改变。第2组患者取得了中度疗效：尿毒症降至正常氮质血症值，DIC综合征及激肽释放酶-激肽系统的抑制作用减轻。第3组患者的DIC综合征消失，激肽释放酶-激肽系统恢复正常，但仍存在高氮质血症。
